Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease of the blood. Evidence suggests that PNH may increase the chances of developing chronic kidney disease (CKD). PNH is characterized ...
Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous Administration The 12-16-week open-label study evaluated Ruxoprubart as ...
Spherix Global Insights today announces the release of its latest Market Dynamix™:Paroxysmal Nocturnal Hemoglobinuria (PNH) (US) 2026 study, revealing a sizable population of patients eligible for ...
These findings suggest that clone size at PNH onset may serve as a prognostic factor for disease burden and MAVEs/TEs, aiding in clinical decision-making about treatment initiation or maintenance. In ...
In his closing thoughts, Dr De Castro provides a final overview of the ASH conference, highlighting updates in PNH treatment. Carlos M. De Castro, MD: I’d love to say we need more studies, studying ...
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease in which the immune system breaks apart the red blood cells (RBCs) in the body. The medical term for this premature rupture of RBCs is ...
The FDA approved the oral factor D inhibitor danicopan (Voydeya) as an add-on therapy to treat extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria (PNH), AstraZeneca announced.
Ilene Weitz, MD, discusses research on several new therapies for paroxysmal nocturnal hemoglobinuria (PNH) with promising clinical impact presented at ASH 2024. The APPLY-PNH and APPOINT-PNH studies ...
In this interview, we spoke with Gloria Gerber, MD, a hematologist and assistant professor of medicine at Johns Hopkins University, about the evolution of treatment for paroxysmal nocturnal ...
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease that can cause fatigue due to anemia. PNH is closely associated with fatigue due to a loss of red blood cells, leading to anemia. This ...
The US Food and Drug Administration (FDA) has approved iptacopan (Fabhalta, Novartis), the first oral monotherapy for both treatment-naive and pretreated adults with paroxysmal nocturnal ...
For patients with paroxysmal nocturnal hemoglobinuria (PNH), crovalimab has emerged as an additional treatment option with a similar safety and efficacy profile to eculizumab, Crovalimab is a novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results